These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8707749)

  • 1. In-vitro susceptibility of Streptococcus pneumoniae to the d- and l-isomers of ofloxacin: interpretive criteria and quality control limits.
    Barry AL; Fuchs PC; Allen SD; Brown SD; Jorgensen JH; Tenover FC
    J Antimicrob Chemother; 1996 Feb; 37(2):365-9. PubMed ID: 8707749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The susceptibility of Streptococcus pneumoniae to levofloxacin and other antibiotics.
    Keller N; Smollen G; Davidson Y; Barzilai A; Keren G; Rubinstein E
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():1-3. PubMed ID: 10404329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of levofloxacin and ofloxacin against Streptococcus pneumoniae.
    Bauernfeind A
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():77-82. PubMed ID: 10404343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antimicrobial activity of levofloxacin against Streptococcus pneumoniae.
    Hu BS; Fung CP; Liu PY; Lau YJ; Shi ZY; Lin YH
    Zhonghua Yi Xue Za Zhi (Taipei); 1997 Oct; 60(4):191-4. PubMed ID: 9439047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of the in-vitro activity of levofloxacin against Streptococcus pneumoniae.
    Reinert RR; Lütticken R; Lemperle M; Bryskier A
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():5-8. PubMed ID: 10404330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
    Frémaux A; Sissia G; Geslin P
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():9-14. PubMed ID: 10404331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro activity of levofloxacin against Streptococcus pneumoniae with various levels of penicillin resistance.
    Thomson KS; Chartrand SA; Sanders CC; Block SL
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():15-9. PubMed ID: 10404332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levofloxacin in vitro activity against bacteremic isolates of Streptococcus pneumoniae. Franklin County Pneumonia Study Group.
    Plouffe JF
    Diagn Microbiol Infect Dis; 1996 May; 25(1):43-5. PubMed ID: 8831044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin.
    Drugeon HB; Juvin ME; Bryskier A
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():55-9. PubMed ID: 10404339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of levofloxacin (l-ofloxacin), ofloxacin and ciprofloxacin against clinical isolates of Streptococcus pneumoniae obtained in England and Wales.
    Johnson AP; Speller DC; Warner M; Domingue G
    J Antimicrob Chemother; 1996 Nov; 38(5):907-8. PubMed ID: 8961064
    [No Abstract]   [Full Text] [Related]  

  • 11. Susceptibility of multi-resistant Streptococcus pneumoniae to ciprofloxacin, ofloxacin and levofloxacin.
    Fuchs PC; Barry AL; Brown SD
    J Antimicrob Chemother; 1997 May; 39(5):671-2. PubMed ID: 9184374
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative in vitro activity of levofloxacin, ofloxacin, and ciprofloxacin against ocular streptococcal isolates.
    Miller D; Alfonso EC
    Cornea; 2004 Apr; 23(3):289-93. PubMed ID: 15084863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interpretive criteria and quality control for antimicrobial susceptibility tests of levofloxacin.
    Barry A; Fuchs P; Tenover F; Allen S; Hardy D; Jorgensen J; McLaughlin J; Reller L
    Eur J Clin Microbiol Infect Dis; 1994 Oct; 13(10):822-6. PubMed ID: 7889952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides.
    Hunt Gerardo S; Citron DM; Claros MC; Goldstein EJ
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2413-5. PubMed ID: 8891154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity.
    Davies BI; Maesen FP
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():83-90. PubMed ID: 10404344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro antibacterial activity of levofloxacin against hospital isolates: a multicentre study.
    Soussy CJ; Cluzel M; Ploy MC; Kitzis MD; Morel C; Bryskier A; Courvalin P
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():43-50. PubMed ID: 10404337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae.
    George J; Morrissey I
    J Antimicrob Chemother; 1997 Jun; 39(6):719-23. PubMed ID: 9222040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae.
    Madaras-Kelly KJ; Demasters TA
    Diagn Microbiol Infect Dis; 2000 Aug; 37(4):253-60. PubMed ID: 10974576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis.
    Rastogi N; Goh KS; Bryskier A; Devallois A
    Antimicrob Agents Chemother; 1996 Jul; 40(7):1610-6. PubMed ID: 8807049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.